Results 51 to 60 of about 75,567 (173)

Use of integrase-minus lentiviral vector for transient expression [PDF]

open access: yes, 2012
Objective: Lentivirus-derived vectors are among the most promising viral vectors for gene therapy which is currently available, but their use in clinical practice is limited due to associated risk of insertional mutagenesis.
Azadeh, H.   +5 more
core   +2 more sources

Approaches to repurposing reverse transcriptase antivirals in cancer

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
This review highlights the role of reverse transcriptase (RT) inhibition in cellular regulation associated with non‐terminal repeat retrotransposons and endogenous retroviruses. Based on their pleiotropic characteristics, RT inhibitors (RTIs) are discussed as potential anticancer agents.
Richard Head   +2 more
wiley   +1 more source

Brujita Integrase: A Simple, Arm-Less, Directionless, and Promiscuous Tyrosine Integrase System [PDF]

open access: yesJournal of Molecular Biology, 2016
Mycobacteriophage Brujita is an unusual temperate phage in which establishment of superinfection immunity is dependent on chromosomal integration. Integration is mediated by a non-canonical tyrosine integrase (Int) lacking an N-terminal domain typically associated with binding to arm-type sites within the phage attachment site (attP).
Bryce L. Lunt, Graham F. Hatfull
openaire   +3 more sources

Histone H2AX Is Phosphorylated at Sites of Retroviral DNA Integration but Is Dispensable for Postintegration Repair [PDF]

open access: yes, 2004
The histone variant H2AX is rapidly phosphorylated (denoted {gamma}H2AX) in large chromatin domains (foci) flanking double strand DNA (dsDNA) breaks that are produced by ionizing radiation or genotoxic agents and during V(D)J recombination.
Bonner, William   +8 more
core   +1 more source

Factors Influencing the Binding of HIV‐1 Protease Inhibitors: Insights from Machine Learning Models

open access: yesChemMedChem, Accepted Article.
HIV‐1 protease inhibitors are crucial for antiviral therapies targeting acquired immunodeficiency syndrome (AIDS). Hundreds of HIV‐1 protease complexes with various ligands have been resolved and deposited in the Protein Data Bank. However, binding affinity measurements for these ligands are not always available.
Yaffa Shalit, Inbal Tuvi-Arad
wiley   +1 more source

HIV Integrase Inhibitors

open access: yes, 2013
n ...
Métifiot, Mathieu   +2 more
openaire   +3 more sources

Dynein Regulators Are Important for Ecotropic Murine Leukemia Virus Infection [PDF]

open access: yes, 2016
Indexación: Web of Science.During the early steps of infection, retroviruses must direct the movement of the viral genome into the nucleus to complete their replication cycle.
Arriagada, Gloria   +4 more
core   +1 more source

A Randomized Phase 1 Study Evaluating Pharmacokinetics, Safety, and Tolerability of a High‐Concentration, Long‐Acting Cabotegravir Formulation in Adults Without HIV

open access: yesClinical Pharmacology in Drug Development, EarlyView.
Abstract Long‐acting (LA) cabotegravir 200‐mg/mL (CAB200) injections are approved for HIV‐1 prevention and as a complete LA HIV‐1 treatment regimen with rilpivirine. A high‐concentration suspension formulation, cabotegravir 400 mg/mL (CAB400‐D), was developed to enable less frequent dosing and self‐administration. This phase 1, double‐blind, randomized
Kelong Han   +16 more
wiley   +1 more source

Evolution of Integrase Resistance During Failure of Integrase Inhibitor-Based Antiretroviral Therapy [PDF]

open access: yesJAIDS Journal of Acquired Immune Deficiency Syndromes, 2010
Although integrase inhibitors are highly effective in the management of drug-resistant HIV, some patients fail to achieve durable viral suppression. The long-term consequences of integrase inhibitor failure have not been well defined.We identified 29 individuals who exhibited evidence of incomplete viral suppression on a regimen containing an integrase
Wei Huang   +11 more
openaire   +3 more sources

Nature Inspired Delivery Vehicles for CRISPR‐Based Genome Editing

open access: yesSmall, EarlyView.
The review highlights nature‐inspired nanocarriers for CRISPR delivery, emphasizing viral vectors, extracellular vesicles, liposomes, and lipid nanoparticles. It discusses their roles in improving specificity, minimizing immunogenicity, and overcoming barriers in genome editing. Recent advancements, challenges, and therapeutic applications are explored,
Elizabeth Maria Clarissa   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy